Telomir Pharmaceuticals Submits IND for Lead Cancer Drug Telomir-1 in Triple-Negative Breast Cancer

summarizeSummary

Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn), its lead candidate for advanced and metastatic Triple-Negative Breast Cancer. This is a critical milestone for the company, especially given its recent 'going concern' warning disclosed in the 10-K on March 17, 2026, and the highly dilutive acquisition approved on March 27, 2026. The successful clearance of this IND and subsequent initiation of a Phase 1/2 clinical trial would provide a much-needed positive catalyst and demonstrate progress in their pipeline, which is essential for a small biotech facing financial challenges. Investors should monitor FDA feedback and the planned trial initiation for further developments.

check_boxKey Events

• IND Application Submitted

  Telomir Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn).

• Targeting Triple-Negative Breast Cancer

  The lead candidate, Telomir-1, is intended for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).

• Phase 1/2 Trial Planned

  Subject to FDA clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy in TNBC patients.

• Preclinical Efficacy and Safety

  Preclinical studies showed Telomir-Zn reduced tumor growth and metastatic dissemination in TNBC models, with no treatment-related adverse or dose-limiting toxicities observed in GLP safety studies.

auto_awesomeAnalysis

Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn), its lead candidate for advanced and metastatic Triple-Negative Breast Cancer. This is a critical milestone for the company, especially given its recent 'going concern' warning disclosed in the 10-K on March 17, 2026, and the highly dilutive acquisition approved on March 27, 2026. The successful clearance of this IND and subsequent initiation of a Phase 1/2 clinical trial would provide a much-needed positive catalyst and demonstrate progress in their pipeline, which is essential for a small biotech facing financial challenges. Investors should monitor FDA feedback and the planned trial initiation for further developments.